 Yttrium Radioisotopes
"Yttrium Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
| Descriptor ID |
D015021
|
| MeSH Number(s) |
D01.268.558.975.500.800 D01.268.956.890.500.800 D01.496.749.960 D01.496.943.800 D01.552.550.975.500.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Yttrium Radioisotopes".
Below are MeSH descriptors whose meaning is more specific than "Yttrium Radioisotopes".
This graph shows the total number of publications written about "Yttrium Radioisotopes" by people in this website by year, and whether "Yttrium Radioisotopes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 | | 2007 | 8 | 0 | 8 | | 2008 | 7 | 4 | 11 | | 2009 | 9 | 2 | 11 | | 2010 | 4 | 0 | 4 | | 2011 | 1 | 1 | 2 | | 2013 | 4 | 3 | 7 | | 2014 | 2 | 1 | 3 | | 2016 | 3 | 0 | 3 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 1 | 2 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Yttrium Radioisotopes" by people in Profiles.
-
Malavia M, Eliason G, Eggers LA, Arne A, Marchak K, Hart J, Lindquist J, Trivedi P, Casadaban L. Yttrium-90 radioembolization for primary and metastatic liver tumors exhibiting arterial-phase hypovascularity. Sci Rep. 2026 Jan 15; 16(1):4588.
-
Kaya NA, Tai D, Lim X, Lim JQ, Lau MC, Goh D, Phua CZJ, Wee FYT, Joseph CR, Lim JCT, Neo ZW, Ye J, Cheung L, Lee J, Loke KSH, Gogna A, Yao F, Lee MY, Shuen TWH, Toh HC, Hilmer A, Chan YS, Lim TK, Tam WL, Choo SP, Yeong J, Zhai W. Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma. J Immunother Cancer. 2023 08; 11(8).
-
Hamad A, Aziz H, Kamel IR, Diaz DA, Pawlik TM. Yttrium-90 Radioembolization: Current Indications and Outcomes. J Gastrointest Surg. 2023 03; 27(3):604-614.
-
Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 12; 6(12):1025-1035.
-
Lentz RW, Messersmith WA. Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases. J Clin Oncol. 2021 12 10; 39(35):3887-3889.
-
Pandey MK, DeGrado TR. Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects. Curr Radiopharm. 2021; 14(4):325-339.
-
Gordon AC, Gates VL, White SB, Harris KR, Procissi D, Zhang Z, Li W, Samaan D, Nicolai JR, Mouli SK, Sato KT, Ryu RK, Omary RA, Salem R, Lewandowski RJ, Larson AC. Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model. J Vasc Interv Radiol. 2021 01; 32(1):23-32.e1.
-
Xu J, Yang J, Gonzalez R, Fisher DR, Miao Y. Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized a-Melanocyte-Stimulating Hormone Peptide. Cancer Biother Radiopharm. 2019 Nov; 34(9):597-603.
-
Siman W, Mikell JK, Mawlawi OR, Mourtada F, Kappadath SC. Dose volume histogram-based optimization of image reconstruction parameters for quantitative 90 Y-PET imaging. Med Phys. 2019 Jan; 46(1):229-237.
-
Bandara N, Stott Reynolds TJ, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ. Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer. Nucl Med Biol. 2018 Jul - Aug; 62-63:71-77.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|